The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...

The peptide structure of Tirzepatide includes modifications that are believed to increase its stability and extend its activity, potentially leading to more sustained metabolic impacts.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Hines Jr Professor of Medicine at Yale University School of Medicine Tirzepatide decreases heart size to improve cardiac structure, function In a secondary analysis of the SUMMIT trial ...

The test of tirzepatide, brand named Zepbound ... Kramer also led a companion study that examined how the drug affected the structure and function of participants' hearts. MRIs showed beneficial ...

Tirzepatide combines synthetic mimics of two ... Importantly, this "type of therapy does not interfere with the normal structure of the body" unlike endoscopic surgery or bariatric surgery ...